Defendant Name: Northwest Biotherapeutics, Inc.

Defendant Type: Public Company
SIC Code: 2834
CUSIP: 66737P60

Document Reference: 34-87281

Document Details

Legal Case Name In the Matter of Northwest Biotherapeutics, Inc.
Document Name Order Instituting Cease-and-Desist Proceedings, Pursuant to Section 21C of the Securities Exchange Act of 1934, Making Findings, and Imposing and Cease-and-Desist Order
Document Date 10-Oct-2019
Document Format Administrative Proceeding
File Number 3-19582
AAER 4099
Allegation Type Issuer Reporting and Disclosure
Document Summary On October 10, 2019, the SEC instituted settled cease-and-desist proceedings against Northwest Biotherapeutics, Inc. ("Respondent"). The SEC stated: "These proceedings involve violations of the federal securities laws in connection with the Respondent's Internal Control over Financial Reporting ("ICFR"). Respondent failed to create and implement effective ICFR for twelve consecutive annual reporting periods from 2007 through 2018."

Disgorgement & Penalty Information

Resolutions
Cease and Desist Order
Compliance Related Independent Consultant
Other Compliance Related Undertaking
Certify compliance with Undertakings to SEC
Cooperation Before the Resolution
Remedial Acts or Efforts Before the Resolution
Monetary Penalties:

Civil Penalty

Individual:     $250,000.00 Shared:    

Related Documents:

34-87281-s 10-Oct-2019 Administrative Summary
SEC Files Settled Action Against Biotechnology Company Related to Unremediated Material Weaknesses Spanning Twelve Years
The SEC stated that: "[It] filed a settled action against Northwest Biotherapeutics (NWBO) for failing to maintain internal control over financial reporting (ICFR) for twelve consecutive annual reporting periods. In each of its annual Form 10-K filings with the Commission over more than a decade, NWBO disclosed material weaknesses, many of which recurred year after year, with insufficient effort at remediation."